Prof. Giuseppe Curigliano

Giuseppe Curigliano, M.D., Ph.D., is a full professor of medical oncology at the University of Milano and chief of the Clinical Division of Early Drug Development at the European Institute of Oncology, Milano, Italy. He is an expert in the field of advanced drug development in solid tumors, with a specific interest in breast cancer. He has contributed to the development of many anticancer treatments available as standard of care in the treatment of multiple solid tumors. Since 2001, he has been a tenure-track and full-time cancer specialist at the European Institute of Oncology—one of the world’s leading cancer research institutes and the premier cancer center in Italy, third in Europe and twelfth globally. He serves as a member of the Italian Higher Health Council. He serves ESMO as chair of the Clinical Practice Guidelines Committee. He was awarded the first ESO Umberto Veronesi Award in Vienna in 2017 and the Fellowship of the European Academy of Cancer Sciences in Paris in 2017. He was identified by Clarivate™ as one of the world’s most influential researchers in 2022 and 2023. He has contributed to over 670 peer-reviewed publications.